CONFIDENTIALITY & DISCLAIMER
This presentation has been prepared by Chemesis Inc. (the “Company”,
or “Chemesis”) for the purpose of conveying certain confidential
information to you regarding our business.
References to the "presentation" include any written or oral information
that has been, or may be supplied to you by, or on behalf of the
Company in connection with this presentation including any further
inquiries that you may make in respect to this presentation. This
presentation has been furnished to you on a confidential basis solely
for the purpose of enabling you to evaluate a potential investment in
our Company.
This presentation and the information contained herein is confidential.
Neither you nor your employees, directors, agents, representatives or
advisors may copy, reproduce or distribute this presentation, in whole
or in part, to anyone without the prior written consent of Biolab.
By accepting this presentation, you agree to keep confidential all
information contained herein, and to use this presentation for the
sole purpose of evaluating our business. Chemesis shall not be liable
for any direct, indirect or consequential loss or damages suffered by
you in reliance upon any information contained in, or as a result of
any omission of information from, this presentation or any other
information furnished to you in connection herewith, and any such
liability is expressly disclaimed.
This presentation does not constitute an offer to sell any securities to,
or a solicitation of an offer to buy any securities from, any person in
any state or other jurisdiction. Any offer or sale of securities of will
only be made pursuant to a mutually acceptable written securities
 SAFE HARBOR
This presentation contains forward-looking statements. With the
exception of historical facts, or those incorporated by reference, all
statements within this presentation are forward-looking statements.
Forward-looking statements include, but are not limited to, all
statements regarding the future financial position, business strategy,
budgets, projected revenue and costs, and plans and objectives of
management for future operations of Chemesis. In addition,
forward-looking statements can generally be identified by the use
of terminology such as “may”, “will”, “expects”, “intends”, “plans”,
“projects”, “estimates”, “anticipates”, “believes”, as well as similar
terminology and expressions, or the negative variations thereof.
The Company has based these forward-looking statements on its
current expectations and projections about future events. These
forward-looking statements are not guarantees, and are subject to
known and unknown risks, uncertainties and assumptions that may
cause the actual results of Chemesis to differ materially from the
proposed results in such statements. Although Chemesis believes that
the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove
to have been correct. Important factors that could cause actual
results to differ materially from proposed expectations include, but
are not limited to, the Company’s ability to fund its future growth,
implement its business strategy, obtain marijuana licenses from
California, design, build and operate processing facilities and
dispensaries, and comply with applicable state and local laws and
regulations. All subsequent written and oral forward-looking
statements attributable to Chemesis, or persons acting on behalf are
of Chemesis, expressly qualified in their entirety by the foregoing.
Except as required by law, Chemesis assumes no duty to update or
revise its forward-looking statements.
 and and

and will
grow and
and
 n
and

and
and .
Chemesis has
and
and

and
 and

and and
 ap

ap and
pounds
and
Projections

�CHEMESIS
 Year 1 Year 2 Year 3 Year 4

REVENUES

Total Revenues $ 27,662,252 $ 56,809,701 $ 68,758,064 $ 79,973,398

Growth Rate 105% 21% 16%

EXPENSES

Materials $ 13,031,130 $ 22,367,130 $ 26,114,185 $ 29,837,240

SG&A Expenses $ 3,283,459 $ 3,264,714 $ 4,543,693 $ 5,713,861

TOTAL $ 16,314,589 $ 25,631,844 $ 30,657,878 $ 35,551,101

Operating Income (Loss) $ 11,347,662 $ 31,077,857 $ 38,100,186 $ 44,422,297

Taxes $ 3,063,869 $ 8,391,021 $ 10,287,050 $ 11,994,020

Net Income (Loss) $ 8,283,793 $ 22,686,836 $ 27,813,136 $ 32,428,277

 Year 1 Year 2 Year 3 Year 4

REVENUES

Total Revenues $ 2,133,144 $ 5,074,812 $ 5,638,680 $ 6,766,416

Growth Rate 1 % 11% 20%

EXPENSES

Materials $ 169,000 $ 200,000 $ 220,000 $ 256,667

SG&A Expenses $ 1,540,820 $ 2,312,913 $ 2,310,401 $ 2,593,427

TOTAL $ 1,709,820 $ 2,512,913 $ 2,530,401 $ 2,850,094

Operating Income (Loss) $ 423,324 $ 2,561,899 $ 3,108,279 $ 3,916,322

Taxes $ 114,297 $ 691,712 $ 839,235 $ 1,057,407

Net Income (Loss) $ 309,026 $ 1,870,186 $ 2,269,043 $ 2,858,915

 Colombia
Year 1 Year 2 Year 3 Year 4

REVENUES
Total Revenues $ 5 954 5 $ 6 4 $ 6 5 5 $ 59 46 6

Growth Rate 49%

95% 56%
126% 56%
127%

EXPENSES

Materials $ 45 $ 5 $ 99 4 $45 9
SG&A Expenses $9 54 $ 49 95 $ 46 $56 5 9

TOTAL
Operating Income (Loss) $45 6 5 $ 9 4 99 $ 4 6 $ 49 4 54

Taxes $ 565 544 $ 54 5 $ $ 6 6 5

Net Income (Loss) $ 5 $6 66 6 $ 4 9 595 $ 4 9
Total Shares Outstanding in Shell 6 4 6

Vend -In Shares ( 36 Month Escrow ) 4 46 4

Total Shares Outstanding 64, 64,760

Warrants Outstanding ( $2 Exercise Price ) 4 99 4

Options Outstanding ( $ Exercise Price ) 5

Fully Diluted Issued & Outstanding 74,364,232